You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Johnson and Johnson
Merck
Baxter
Moodys

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,895,557

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,895,557 protect, and when does it expire?

Patent 8,895,557 protects YONDELIS and is included in one NDA.

Protection for YONDELIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in thirty-six countries.

Summary for Patent: 8,895,557
Title:Pharmaceutical formulations of ecteinascidin compounds
Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
Inventor(s): Beijnen; Jacob Hendrik (Amsterdam, NL), Nuijen; Bastiaan (Amsterdam, NL), Salve; Pilar Calvo (Madrid, ES), Barreira; Maria Tobio (Madrid, ES)
Assignee: Pharma Mar, S.A., Sociedad Unipersonal (Madrid, ES)
Application Number:11/261,876
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Drugs Protected by US Patent 8,895,557

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,895,557

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 051653   Start Trial
Argentina 110986   Start Trial
Austria 368461   Start Trial
Australia 2005227421   Start Trial
Brazil PI0517238   Start Trial
Canada 2520979   Start Trial
China 102018714   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
AstraZeneca
Colorcon
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.